ReviewEuropean respiratory review : an official journal of the European Respiratory Society2013
Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.
Review in European respiratory review : an official journal of the European Respiratory Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.BioMed research international · 2015Trial
- Sex and gender differences during the lung lifespan: unveiling a pivotal impact.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- ADP-ribose hydrolases: biological functions and potential therapeutic targets.Expert reviews in molecular medicine · 2024Review
- Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix.Frontiers in pharmacology · 2024Article
- Sleep apnea syndrome associated with gonadal hormone imbalance (Review).Biomedical reports · 2023Review
- New Perspectives on Sex Steroid Hormones Signaling in Cancer-Associated Fibroblasts of Non-Small Cell Lung Cancer.Cancers · 2023Review
- Article
- Sex and gender in respiratory physiology.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- (ADP-ribosyl)hydrolases: structure, function, and biology.Genes & development · 2020Review
- ARH1 in Health and Disease.Cancers · 2020Review
- Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways.Biochemical pharmacology · 2019Review
- Multi-walled carbon nanotubes inhibit estrogen receptor expression in vivo and in vitro through transforming growth factor beta1.NanoImpact · 2019Article
- Endocrine regulation of lung disease and inflammation.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Human Pluripotent Stem Cell-DerivedCancer research · 2017Article
- Gender, Estrogen, and Obliterative Lesions in the Lung.International journal of endocrinology · 2017Review
- Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.Endocrine-related cancer · 2016Article
- Benign metastasizing leiomyomas in the lungs: a case study.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2016Article
- Review
- Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer.European respiratory review : an official journal of the European Respiratory Society · 2014Review
- Future perspectives on rare pulmonary diseases and rare presentations of common disorders.European respiratory review : an official journal of the European Respiratory Society · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Sex prevalence in lung disease suggests that sex-specific hormones may contribute to the pathogenesis and/or progression of at least some lung diseases, such as lung adenocarcinoma, lymphangioleiomyomatosis (LAM) and benign metastasising leiomyoma (BML). Oestrogen is an important hormone in normal lung development and in the pathogenesis of female predominant pulmonary diseases. In vivo and in vitro studies have facilitated our understanding of disease pathogenesis and discovery of potential therapeutic targets. Oestrogen promoted disease progression in cell and animal models of lung adenocarcinoma, LAM and BML. Specifically, oestrogen enhanced tumour growth and metastasis in animal models of these diseases. Furthermore, 17β-estradiol (E2), the most abundant form of oestrogen in humans, increased the size and proliferation of cultured cells of lung adenocarcinoma and LAM. Coupled with the known mechanisms of oestrogen metabolism and signalling, these model systems may provide insights into the diverse effects of oestrogen and other hormones on lung diseases. Anti-oestrogen treatments that target key events of oestrogen synthesis or signalling, such as aromatase activity, oestrogen receptors and signalling pathways, may offer additional opportunities for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.